[1] Lovell R M, Ford A C. Global prevalence of and risk factors for irrita-ble bowel syndrome:A meta-analysis[J]. Clinical Gastroenterology & Hepatology, 2012, 10(7):712-721.
[2] Devanarayana N M, Rajindrajith S, Pathmeswaran A, et al. Epidemiolo-gy of irritable bowel syndrome in children and adolescents in Asia[J]. Journal of Pediatric Gastroenterology & Nutrition, 2015, 60(6):792-798.
[3] Drossman D A. Functional gastrointestinal disorders:History, patho-physiology, clinical features and Rome IV[J]. Gastroenterology, 2016, 150(6):1262-1279.
[4] Hyams J S, Di L C, Saps M, et al. Functional disorders:Children and adolescents[J]. Gastroenterology, 2016.
[5] Chogle A, Mintjens S, Saps M. Pediatric IBS:an overview on pathophys-iology, diagnosis and treatment[J]. Pediatric Annals, 2014, 43(4):76-82.
[6] Ringel Y, Maharshak N. Intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome[J]. American Journal of Physiology Gastrointestinal & Liver Physiology, 2013, 305(8):G529.
[7] 王黎黎. 益生菌治疗肠易激综合征机制和疗效的研究进展[J]. 海南医学院学报, 2013, 19(12):1781-1784. Wang Lili. Research progress in probiotic therapy and therapeutic effect for irritable bowel syndrome[J]. Journal of Hainan Medical University, 2013, 19(12):1781-1784.
[8] Whitehead W E, Engel B T, Schuster M M. Irritable bowel syndrome[J]. Digestive Diseases & Sciences, 1980, 25(6):404-413.
[9] Ford A C, Lacy B E, Talley N J. Irritable bowel syndrome[J]. New Eng-land Journal of Medicine, 2017, 376(26):2566-2578.
[10] Bertiauxvandaële N, Youmba S B, Belmonte L, et al. The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype[J]. American Journal of Gastroenterology, 2011, 106(12):2165-2173.
[11] Ringel Y, Ringelkulka T. The intestinal microbiota and irritable bowel syndrome[J]. Journal of Clinical Gastroenterology, 2015, 49(Suppl 1):S56.
[12] Schmulson M, Pulido-London D, Rodriguez O, et al. Lower serum IL-10 is an independent predictor of IBS among volunteers in Mexico[J]. American Journal of Gastroenterology, 2012, 107(5):747-753.
[13] Qin S Y, Jiang H X, Lu D H, et al. Association of interleukin-10 poly-morphisms with risk of irritable bowel syndrome:A meta-analysis[J]. World J Gastroenterol, 2013, 19(48):9472-9480.
[14] Hua M C, Chao H C, Yao T C, et al. Investigation of interleukin-10 promoter polymorphisms and interleukin-10 levels in children with ir-ritable bowel syndrome[J]. Gut & Liver, 2013, 7(4):430-436.
[15] Bashashati M, Rezaei N, Shafieyoun A, et al. Cytokine imbalance in ir-ritable bowel syndrome:A systematic review and meta-analysis[J]. Neurogastroenterology & Motility, 2014, 26(7):1036-1048.
[16] Holtmann G J, Ford A C, Talley N J. Pathophysiology of irritable bow-el syndrome[J]. Lancet Gastroenterology & Hepatology, 2016, 1(2):133-146.
[17] Belmonte L, Beutheu Y S, Bertiaux-Vandaële N, et al. Role of toll like receptors in irritable bowel syndrome:differential mucosal im-mune activation according to the disease subtype[J]. PloS One, 2012, 7(8):e42777.
[18] Brint E K, Macsharry J, Fanning A, et al. Differential expression of toll-like receptors in patients with irritable bowel syndrome[J]. Ameri-can Journal of Gastroenterology, 2011, 106(2):329-336.
[19] Koçak E, Akbal E, Köklü S, et al. The colonic tissue levels of TLR2, TLR4 and nitric oxide in patients with irritable bowel syndrome[J]. In-ternal Medicine, 2016, 55(9):1043-1048.
[20] Dlugosz A, Zakikhany K, Acevedo N, et al. Increased expression of toll-like receptors 4, 5, and 9 in small bowel mucosa from patients with irritable bowel syndrome[J]. Biomed Research International, 2017, 2017(11):9624702.
[21] Reid G. Probiotics:Definition, scope and mechanisms of action[J]. Best Practice & Research Clinical Gastroenterology, 2016, 30(1):17-25.
[22] Nagpal R, Yadav H, Kumar M, et al. Probiotics, prebiotics and synbi-otics[M]//Food Biotechnology. Berlin Heidelberg Springer, 2008:1-66.
[23] Panigrahi P. Probiotics and prebiotics in neonatal necrotizing enteroco-litis:New opportunities for translational research[J]. Pathophysiology, 2014, 21(1):35-46.
[24] Sarkar A, Mandal S. Bifidobacteria-insight into clinical outcomes and mechanisms of its probiotic action[J]. Microbiological Research, 2016, 192:159-171.
[25] De K S, Tobin M C, Forsyth C B, et al. Regulation of intestinal im-mune responses through tlr activation:implications for pro-and prebi-otics[J]. Frontiers in Immunology, 2014, 5(60):60.
[26] Hörmannsperger G, Haller D, Haller D, et al. Molecular crosstalk of probiotic bacteria with the intestinal immune system:clinical rele-vance in the context of inflammatory bowel disease[J]. International Journal of Medical Microbiology, 2010, 300(1):63-73.
[27] Nébotvivinus M, Harkat C, Bzioueche H, et al. Multispecies probiotic protects gut barrier function in experimental models[J]. World Journal of Gastroenterology, 2014, 20(22):6832-6843.
[28] 姚树坤. 益生菌治疗肠易激综合征的临床研究进展[J]. 中华消化杂志, 2013, 33(12):806-808. Yao shukun. Clinical research advance in probiotic therapy for irritable bowel syndrome[J]. Chinese Journal of Digestion, 2013, 33(12):806-808.
[29] Kumar S, Shukla R, Ranjan P, et al. Interleukin-10:A compelling therapeutic target in patients with irritable bowel syndrome[J]. Clini-cal Therapeutics, 2017, 39(3):632-643.
[30] Shi C Z, Chen H Q, Liang Y, et al. Combined probiotic bacteria pro-motes intestinal epithelial barrier function in interleukin-10-gene-de-ficient mice[J]. World Journal of Gastroenterology, 2014, 20(16):4636.
[31] Jeon S G, Kayama H, Ueda Y, et al. Probiotic Bifidobacterium breve induces IL-10-producing Tr1 cells in the colon[J]. PloS Pathogens, 2012, 8(5):e1002714.
[32] Noguchi S, Hattori M, Sugiyama H, et al. Lactobacillus plantarum NRIC1832 enhances IL-10 production from CD4+ T cells in vitro[J]. Bioscience Biotechnology & Biochemistry, 2012, 76(10):1925-1931.
[33] Rebeca M, Florian C, Sylvie M, et al. Effects in the use of a genetical-ly engineered strain of Lactococcus lactis delivering in situ IL-10 as a therapy to treat low-grade colon inflammation[J]. Human Vaccines & Immunotherapeutics, 2014, 10(6):1611-1621.
[34] Compare D, Rocco A, Coccoli P, et al. Lactobacillus casei DG and its postbiotic reduce the inflammatory mucosal response:An ex-vivo or-gan culture model of post-infectious irritable bowel syndrome[J]. Bmc Gastroenterology, 2017, 17(1):53.
[35] Hua M C, Lai M W, Kuo M L, et al. Decreased interleukin-10 secre-tion by peripheral blood mononuclear cells in children with irritable bowel syndrome[J]. Journal of Pediatric Gastroenterology & Nutrition, 2011, 52(4):376-381.
[36] Patel R M, Myers L S, Kurundkar A R, et al. Probiotic bacteria in-duce maturation of intestinal claudin 3 expression and barrier function[J]. American Journal of Pathology, 2012, 180(2):626-635.
[37] Dai C, Zhao D H, Jiang M. VSL#3 probiotics regulate the intestinal epithelial barrier in vivo and in vitro via the p38 and ERK signaling pathways[J]. International Journal of Molecular Medicine, 2012, 29(2):202-208.
[38] Didari T, Mozaffari S, Nikfar S, et al. Effectiveness of probiotics in irri-table bowel syndrome:Updated systematic review with meta-analysis[J]. World Journal of Gastroenterology, 2015, 21(10):3072-3084.
[39] Abbas Z, Yakoob J, Jafri W, et al. Cytokine and clinical response to Saccharomyces boulardii therapy in diarrhea-dominant irritable bowel syndrome:A randomized trial[J]. European Journal of Gastroenterology & Hepatology, 2014, 26(6):630-639.
[40] Stevenson C, Blaauw R, Fredericks E, et al. Randomized clinical trial:Effect of Lactobacillus plantarum, 299v on symptoms of irritable bow-el syndrome[J]. Clinical Nutrition, 2014, 30(10):1151-1157.
[41] Wojtyniak K, Horvath A, Dziechciarz P, et al. Lactobacillus casei rhamnosus Lcr35 in the management of functional constipation in chil-dren:A randomized trial[J]. Journal of Pediatrics, 2017, 184:101-105.
[42] Doron S, Snydman D R. Risk and safety of probiotics[J]. Clinical Infec-tious Diseases, 2015, 60(Suppl 2):S129.
[43] Ducrotté P, Sawant P, Jayanthi V. Clinical trial:Lactobacillus planta-rum 299v (DSM 9843) improves symptoms of irritable bowel syndrome[J]. World Journal of Gastroenterology, 2012, 18(30):4012-4018.
[44] Amirimani B, Nikfam S, Albaji M, et al. Probiotic vs Placebo in irrita-ble bowel syndrome:A randomized controlled trial[J]. Middle East Journal of Digestive Diseases, 2013, 5(2):98-102.
